What is Chardan Capital’s Estimate for IPSC FY2025 Earnings?

Century Therapeutics, Inc. (NASDAQ:IPSC) – Chardan Capital issued their FY2025 earnings per share estimates for shares of Century Therapeutics in a research report issued on Monday, March 24th. Chardan Capital analyst Y. Livshits forecasts that the company will post earnings per share of ($0.33) for the year. Chardan Capital currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.61) per share. Chardan Capital also issued estimates for Century Therapeutics’ FY2026 earnings at ($0.64) EPS.

Several other equities analysts have also weighed in on IPSC. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Century Therapeutics in a report on Wednesday, January 22nd. Guggenheim decreased their target price on Century Therapeutics from $12.00 to $5.00 and set a “buy” rating for the company in a research report on Friday, March 21st. Finally, Piper Sandler cut their price target on Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating on the stock in a report on Thursday, March 20th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $5.00.

Century Therapeutics Stock Up 0.2 %

Century Therapeutics stock opened at $0.56 on Thursday. The company has a market capitalization of $47.84 million, a PE ratio of -0.30 and a beta of 1.75. The firm’s fifty day moving average is $0.72 and its 200 day moving average is $1.14. Century Therapeutics has a 12-month low of $0.52 and a 12-month high of $4.43.

Century Therapeutics (NASDAQ:IPSC) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.02. The firm had revenue of $4.18 million for the quarter, compared to analyst estimates of $0.67 million. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.73%.

Institutional Investors Weigh In On Century Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in IPSC. Marshall Wace LLP acquired a new position in Century Therapeutics during the 4th quarter valued at about $36,000. Jane Street Group LLC raised its stake in shares of Century Therapeutics by 166.2% in the fourth quarter. Jane Street Group LLC now owns 48,036 shares of the company’s stock worth $49,000 after purchasing an additional 29,992 shares during the last quarter. Two Sigma Advisers LP bought a new position in shares of Century Therapeutics in the fourth quarter valued at approximately $52,000. Sei Investments Co. purchased a new position in shares of Century Therapeutics during the fourth quarter valued at approximately $53,000. Finally, Two Sigma Investments LP bought a new stake in Century Therapeutics during the fourth quarter worth $67,000. 50.20% of the stock is owned by institutional investors.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.